Trospium
- Generic Name
- Trospium
- Brand Names
- Trosec
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30NO3
- CAS Number
- 47608-32-2
- Unique Ingredient Identifier
- T4Y8ORK057
- Background
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by Indevus Pharmaceutical Inc. and was granted FDA approval in 2007.
- Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
- Associated Conditions
- Overactive Bladder Syndrome (OABS)
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 586
- Registration Number
- NCT06976216
- Locations
- 🇭🇷
Local Institution - 0216, Osijek, Croatia
🇭🇷Local Institution - 0267, Rijeka, Croatia
🇭🇷Local Institution - 0240, Zagreb, Croatia
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 586
- Registration Number
- NCT06976203
- Locations
- 🇫🇮
Local Institution - 0022, Oulu, Pohjois-Pohjanmaa, Finland
🇫🇮Local Institution - 0009, Turku, Varsinais-Suomi, Finland
🇫🇮Local Institution - 0008, Kuopio, Finland
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
- Conditions
- Bipolar-I Disorder With Mania or Mania With Mixed Features
- Interventions
- Other: Placebo
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 274
- Registration Number
- NCT06951698
- Locations
- 🇺🇸
Local Institution - 0058, Bentonville, Arkansas, United States
🇺🇸Local Institution - 0011, Little Rock, Arkansas, United States
🇺🇸Local Institution - 0005, Anaheim, California, United States
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
- Conditions
- Bipolar Disorder Type I With Mania or Mania With Mixed Features
- Interventions
- Other: Placebo
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 274
- Registration Number
- NCT06951711
- Locations
- 🇮🇹
Local Institution - 0056, Pisa, Toscana, Italy
🇮🇹Local Institution - 0007, Siena, Toscana, Italy
🇮🇹Local Institution - 0041, Ancona, Italy
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
- Conditions
- Alzheimer DiseasePsychosis
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1046
- Registration Number
- NCT06947941
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT06937229
- Locations
- 🇺🇸
Local Institution - 2609, Chandler, Arizona, United States
🇺🇸Local Institution - 2620, Canoga Park, California, United States
🇺🇸Local Institution - 2614, San Diego, California, United States
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT06929273
- Locations
- 🇧🇬
Local Institution - 0113, Sliven, Bulgaria
🇺🇸Local Institution - 0120, Glendale, Arizona, United States
🇺🇸Local Institution - 0123, Torrance, California, United States
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 250
- Registration Number
- NCT06882785
- Locations
- 🇯🇵
Local Institution - 0033, Tottori, Japan
🇯🇵Local Institution - 0006, Wakayama, Japan
🇯🇵Local Institution - 0030, Yamagata, Japan
Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT06853171
- Locations
- 🇺🇸
Pillar Clinical Research- Little Rock, Little Rock, Arkansas, United States
🇺🇸NRC Research Institute, Orange, California, United States
🇺🇸CenExel iResearch, LLC, Decatur, Georgia, United States
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Karuna Therapeutics
- Target Recruit Count
- 78
- Registration Number
- NCT06605950
- Locations
- 🇺🇸
Cenexel ACT (Anaheim Clinical Trials), Anaheim, California, United States
🇺🇸Local Institution - 0002, Anaheim, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.